DASL-HiCaP
07 Dec 2020
DASL-HiCaP
NCT04136353
Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (DASL-HiCaP)
–
Cancer Type | Prostate |
---|---|
Trial Type | Treatment |
Phase | Phase III |
Age Range | 18 years and older |
Sex | Male |
Tumour Stream | - |
Cancer Stage | Locally Recurrent or Locally Advanced |
Anticipated Start Date | 2020-01-31 |
Anticipated End Date | 2028-07-31 |
Hospital | Ashford Cancer Centre Research |
---|---|
Clinical Trial Coordinator | Sue Yeend |
syeend@adelaidecancercentre.com.au | |
Phone | 08 8292 2240 |
Principal Investigator | Dr Francis Parnis |
Recruitment Status | Not Yet Recruiting |